Tracking the Potential of Excipients - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Tracking the Potential of Excipients
Excipient producers and industry observers share their perspectives on innovation for excipients.

Pharmaceutical Technology

Excipients used in nano-sized liposomes also offer opportunity, "The pharmaceutical industry has made overtures toward the use of liposomes (or 60 nanometer-sized emulsion droplets) as delivery systems but has yet to accept them fully," reports the BCC Research study. "That acceptance has been stalled, in part because of the lack of precise scientific data on the exact role of lipid-based excipients (oleochemicals) and their influence on adsorption of the drug." The excipients are used to stabilize the liposomes (1).

In addition, fatty acids, alcohols, esters, and ethers are being considered as excipients for nanoparticle matrices. "Minimal amounts of excipients are being used in vivo nanoparticle formulations with similar or enhanced immunogenicity in comparison to that of alum," according to the BCC Research study (1).

A case in point is the work of researchers at Novartis Vaccines and Diagnostics (Emeryville, CA), who developed a lyophilized nanoparticle formulation that suspends the small amount of excipients used (sucrose and mannitol or dioctyl sodium sulfosuccinate with trehalose and mannitol) in polyvinyl alcohol. The formulation also contains adsorbed protein antigen (1, 3).

Calcium phosphate is also being considered as a replacement for aluminum salts, an US Food and Drug Administration-approved adjuvant for vaccines. BioSante Pharmaceuticals (Lincolnshire, IL) uses the excipient in its "CaP" nanotechnology. The company has completed Phase I of a clinical trial on the technology as a vaccine adjuvant and a delivery system. Preclinical results indicate that the CaP nanotechnology also performs well when injected as a facial-line filler. BioSante plans to initiate clinical tests of the technology in 2008 (1).


1. "Excipients in Pharmaceuticals," Report No. PHM010E, BCC Research (Norwalk, CT, 2006).

2. P. Van Arnum, "BASF Advances Nanocoating for Ibuprofen Formulation," Pharm. Technol. 30 (6), 48 (2006).

3. K. O Hagan et al., "A Practical Approach to the Use of Nanoparticles for Vaccine Delivery, J. Pharm. Sci. 95 (12), 2738–2750 (2006).

For analysis and trends in the excipient market, see the article "Measuring Excipient-Market Growth" in the April 2008 issue of Pharmaceutical Technology.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here